Results 181 to 190 of about 3,900,144 (339)

Substance Use and Sex Index version 2 (SUSI‐2): Validation of a brief questionnaire for the measurement of behaviours associated with transmission of blood borne viruses and sexually transmitted infections

open access: yesAddiction, EarlyView.
Abstract Aims This study sought to validate a community‐acceptable Substance Use & Sex Index (SUSI) for use in substance use intervention research. SUSI aims to measure behaviours associated with the transmission of blood‐borne viruses (BBV) and sexually transmitted infections (STI) among people who use substances and incorporate contemporary sexual ...
Brendan Clifford   +9 more
wiley   +1 more source

Rare but relevant: MDMA and hyponatraemia

open access: yesAddiction, EarlyView.
Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Maria Rita Garcia   +2 more
wiley   +1 more source

Psychotropic Drug Use in Korean Patients With Osteoarthritis. [PDF]

open access: yesJ Korean Med Sci
Kang SH   +7 more
europepmc   +1 more source

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. [PDF]

open access: yesEur Neuropsychopharmacol, 2023
Fico G   +13 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden   +10 more
wiley   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

open access: yesAddiction, EarlyView.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer   +3 more
wiley   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

open access: yesAddiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy